<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>COMBIGAN- brimonidine tartrate and timolol maleate solution/ drops </strong><br>Allergan, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
These highlights do not include all the information needed to use COMBIGAN<span class="Sup">®</span> safely and effectively. See full prescribing information for COMBIGAN<span class="Sup">®</span>.<br><br>
COMBIGAN<span class="Sup">®</span> (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%<br>
Initial U.S. Approval: 2007
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta"><span class="Bold">COMBIGAN<span class="Sup">®</span></span> is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> who require adjunctive or replacement therapy due to inadequately controlled IOP; the IOP-lowering of <span class="Bold">COMBIGAN<span class="Sup">®</span></span>
									dosed twice a day was slightly less than that seen with the concomitant administration of timolol maleate ophthalmic solution, 0.5% dosed twice a day and brimonidine tartrate ophthalmic solution, 0.2% dosed three times per day. (<a href="#s1">1</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">One drop in the affected eye(s), twice daily approximately 12 hours apart. (<a href="#s2">2</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Solution containing 2 mg/mL brimonidine tartrate and 5 mg/mL timolol. (<a href="#s3">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>. (<a href="#s5">4.1</a>, <a href="#s9">5.1</a>, <a href="#s11">5.3</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus bradycardia</span>, second or third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>. (<a href="#s6">4.2</a>, <a href="#s10">5.2</a>)
</li>
<li>Neonates and infants (under the age of 2 years). (<a href="#e7">4.3</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this product. (<a href="#s7">4.4</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Potentiation of Respiratory Reactions Including <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> (<a href="#s9">5.1</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span> (<a href="#s10">5.2</a>)
</li>
<li>Obstructive Pulmonary Disease (<a href="#s11">5.3</a>)
</li>
<li>Potentiation of <span class="product-label-link" type="condition" conceptid="4311420" conceptname="Vascular insufficiency">Vascular Insufficiency</span> (<a href="#s12">5.4</a>)
</li>
<li>Increased Reactivity to Allergens (<a href="#s13">5.5</a>)
</li>
<li>Potentiation of <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle Weakness</span> (<a href="#s14">5.6</a>)
</li>
<li>Masking of Hypoglycemic Symptoms in Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus (<a href="#s15">5.7</a>)
</li>
<li>Masking of <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span> (<a href="#s16">5.8</a>)
</li>
<li>Ocular <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<a href="#s17">5.9</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions occurring in approximately 5 to 15% of patients included <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>, conjunctival folliculosis, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>, <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">eye pruritus</span>, ocular burning, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>. (<a href="#s20">6.1</a>)
 </p>
<p class="Highlighta"><br><span class="Bold">
To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-433-8871 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Antihypertensives/cardiac glycosides may lower blood pressure. (<a href="#s28">7.1</a>)
</li>
<li>Concomitant use with systemic beta-blockers may potentiate systemic beta-blockade. (<a href="#s29">7.2</a>)
</li>
<li>Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, <span class="product-label-link" type="condition" conceptid="439846" conceptname="Left heart failure">left ventricular failure</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. (<a href="#s30">7.3</a>)
</li>
<li>Catecholamine-depleting drugs may have additive effects and produce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. (<a href="#s31">7.4</a>)
</li>
<li>Use with CNS depressants may result in an additive or potentiating effect. (<a href="#s32">7.5</a>)
</li>
<li>Digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time. (<a href="#s33">7.6</a>)
</li>
<li>CYP2D6 inhibitors may potentiate systemic beta-blockade. (<a href="#s34">7.7</a>)
</li>
<li>Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine.  (<a href="#s35">7.8</a>)
</li>
<li>Monoamine oxidase inhibitors may result in increased <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. (<a href="#s36">7.9</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Not for use in children below the age of 2 years. Use with caution in children ≥ 2 years of age. (<a href="#s40">8.4</a>) </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 11/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2 <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV Block</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">Cardiogenic Shock</span></a></h2>
<h2><a href="#section-4.3" class="toc">
                        4.3 Neonates and Infants (Under the Age of 2 Years)</a></h2>
<h2><a href="#section-4.4" class="toc">4.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Potentiation of Respiratory Reactions Including <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Obstructive Pulmonary Disease
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Potentiation of <span class="product-label-link" type="condition" conceptid="4311420" conceptname="Vascular insufficiency">Vascular Insufficiency</span>
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Increased Reactivity to Allergens
</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Potentiation of <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle Weakness</span>
</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Masking of Hypoglycemic Symptoms in Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus
</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Masking of <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span>
</a></h2>
<h2><a href="#section-5.9" class="toc">
                        5.9	Ocular <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Contamination of Topical Ophthalmic Products After Use
</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Impairment of Beta-adrenergically Mediated Reflexes During Surgery
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience
</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Antihypertensives/Cardiac Glycosides
</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Beta-adrenergic Blocking Agents
</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Calcium Antagonists
</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Catecholamine-depleting Drugs
</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 CNS Depressants
</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Digitalis and Calcium Antagonists
</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 CYP2D6 Inhibitors
</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Tricyclic Antidepressants
</a></h2>
<h2><a href="#section-7.9" class="toc">7.9 Monoamine Oxidase Inhibitors
</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use
</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE
</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES
</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<p class="First"><span class="Bold">COMBIGAN<span class="Sup">®</span></span> (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> who require adjunctive or replacement therapy due to inadequately controlled IOP; the IOP-lowering of <span class="Bold">COMBIGAN<span class="Sup">®</span></span> dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<p class="First">The recommended dose is one drop of <span class="Bold">COMBIGAN<span class="Sup">®</span></span> in the affected eye(s) twice daily approximately 12 hours apart. If more than one topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart.
</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Solution containing 2 mg/mL brimonidine tartrate and 5 mg/mL timolol (6.8 mg/mL timolol maleate).
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-4.1"></a><p></p>
<h2>4.1 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span></h2>
<p class="First"><span class="Bold">COMBIGAN<span class="Sup">®</span></span> is contraindicated in patients with bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>; a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>; severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> <span class="Italics">[see Warnings and Precautions (<a href="#s9">5.1</a>, <a href="#s11">5.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-4.2"></a><p></p>
<h2>4.2 <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV Block</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">Cardiogenic Shock</span></h2>
<p class="First"><span class="Bold">COMBIGAN<span class="Sup">®</span></span> is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>; second or third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>; overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> <span class="Italics">[see Warnings and Precautions (<a href="#s10">5.2</a>)]</span>; <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e7"></a><a name="section-4.3"></a><p></p>
<h2>
                        4.3 Neonates and Infants (Under the Age of 2 Years)</h2>
<p class="First"><span class="Bold">COMBIGAN<span class="Sup">®</span></span> is contraindicated in neonates and infants (under the age of 2 years).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-4.4"></a><p></p>
<h2>4.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First"><span class="Bold"></span></p>
<p>Local <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have occurred following the use of different components of <span class="Bold">COMBIGAN<span class="Sup">®</span></span>.<span class="Bold">  COMBIGAN<span class="Sup">®</span></span> is contraindicated in patients who have exhibited a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to any component of this medication in the past.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s8"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Potentiation of Respiratory Reactions Including <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>
</h2>
<p class="First"><span class="Bold">COMBIGAN<span class="Sup">®</span></span> contains timolol maleate; and although administered topically can be absorbed systemically. Therefore, the same types of adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> have been reported following systemic or ophthalmic administration of timolol maleate <span class="Italics">[see Contraindications (<a href="#s5">4.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>
</h2>
<p class="First">Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure.
</p>
<p>In patients without a history of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, continued <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. At the first sign or symptom of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="Bold">COMBIGAN<span class="Sup">®</span></span> should be discontinued <span class="Italics">[see Contraindications (<a href="#s6">4.2</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Obstructive Pulmonary Disease
</h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (e.g., <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>) of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease [other than bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, in which <span class="Bold">COMBIGAN<span class="Sup">®</span></span> is contraindicated <span class="Italics">[see Contraindications (<a href="#s5">4.1</a>)]</span>] should, in general, not receive beta-blocking agents, including <span class="Bold">COMBIGAN<span class="Sup">®</span></span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Potentiation of <span class="product-label-link" type="condition" conceptid="4311420" conceptname="Vascular insufficiency">Vascular Insufficiency</span>
</h2>
<p class="First"><span class="Bold">COMBIGAN<span class="Sup">®</span></span> may potentiate syndromes associated with <span class="product-label-link" type="condition" conceptid="4311420" conceptname="Vascular insufficiency">vascular insufficiency</span>.  <span class="Bold">COMBIGAN<span class="Sup">®</span></span><span class="Bold"></span> should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, cerebral or coronary insufficiency, Raynaud's phenomenon, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, or <span class="product-label-link" type="condition" conceptid="312939" conceptname="Thromboangiitis obliterans">thromboangiitis obliterans</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Increased Reactivity to Allergens
</h2>
<p class="First">While taking beta-blockers, patients with a history of <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopy</span> or a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Potentiation of <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle Weakness</span>
</h2>
<p class="First">Beta-adrenergic blockade has been reported to potentiate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> consistent with certain myasthenic symptoms (e.g., <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, and generalized <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>). Timolol has been reported rarely to increase <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in some patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> or myasthenic symptoms.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Masking of Hypoglycemic Symptoms in Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus
</h2>
<p class="First">Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or to diabetic patients (especially those with labile <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are receiving insulin or oral hypoglycemic agents.  Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Masking of <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span>
</h2>
<p class="First">Beta-adrenergic blocking agents may mask certain clinical signs (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>. Patients suspected of developing <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-5.9"></a><p></p>
<h2>
                        5.9	Ocular <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</h2>
<p class="First">
                           Ocular <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been reported with brimonidine tartrate ophthalmic solutions 0.2%, with some reported to be associated with an increase in intraocular pressure <span class="Italics">[see Contraindications (<a href="#s7">4.4</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Contamination of Topical Ophthalmic Products After Use
</h2>
<p class="First">There have been reports of bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface <span class="Italics">[see Patient Counseling Information (<a href="#s57">17</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e18"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Impairment of Beta-adrenergically Mediated Reflexes During Surgery
</h2>
<p class="First">The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures. Some patients receiving beta-adrenergic receptor blocking agents have experienced protracted severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported. For these reasons, in patients undergoing elective surgery, some authorities recommend gradual withdrawal of beta-adrenergic receptor blocking agents.
</p>
<p>If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s19"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience
</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold">COMBIGAN<span class="Sup">®</span></span></p>
<p>In clinical trials of 12 months duration with <span class="Bold">COMBIGAN<span class="Sup">®</span></span>, the most frequent reactions associated with its use occurring in approximately 5% to 15% of the patients included: <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>, conjunctival folliculosis, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>, <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">eye pruritus</span>, ocular burning, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>. The following adverse reactions were reported in 1% to 5% of patients: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>, <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">epiphora</span>, <span class="product-label-link" type="condition" conceptid="4080696" conceptname="Discharge from eye">eye discharge</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">eye dryness</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="374950" conceptname="Edema of eyelid">eyelid edema</span>, eyelid <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, eyelid <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, foreign body sensation, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">oral dryness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="375265" conceptname="Punctate keratitis">superficial punctate keratitis</span>, and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span>.
</p>
<p>Other adverse reactions that have been reported with the individual components are listed below.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold">Brimonidine Tartrate (0.1%-0.2%)</span></p>
<p>Abnormal taste, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="374347" conceptname="Blepharoconjunctivitis">blepharoconjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="380117" conceptname="Conjunctival edema">conjunctival edema</span>, <span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">conjunctival hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">follicular conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorder</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (primarily <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">colds</span> and <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infections</span>), <span class="product-label-link" type="condition" conceptid="4265426" conceptname="Hordeolum">hordeolum</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, lid disorder, <span class="product-label-link" type="condition" conceptid="4171214" conceptname="Nasal mucosa dry">nasal dryness</span>, ocular <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinus infection</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, tearing, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span>, <span class="product-label-link" type="condition" conceptid="4202518" conceptname="Vitreous detachment">vitreous detachment</span>, <span class="product-label-link" type="condition" conceptid="313498" conceptname="Vitreous strands">vitreous disorder</span>, <span class="product-label-link" type="condition" conceptid="4034681" conceptname="Vitreous floaters">vitreous floaters</span>, and worsened visual acuity.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold">Timolol (Ocular Administration)</span></p>
<p><span class="Italics">Body as a whole</span>: <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>;  <span class="Italics">Cardiovascular</span>: <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>, cerebral vascular <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">claudication</span>, <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">cold hands</span> and feet, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, Raynaud's phenomenon, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, and worsening of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>;  <span class="Italics">Digestive</span>: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>;  <span class="Italics">Immunologic</span>: <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic lupus erythematosus</span>;  <span class="Italics">Nervous System/Psychiatric</span>: Increase in signs and symptoms of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, behavioral changes and <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">psychic disturbances</span> including <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>;  <span class="Italics">Skin</span>: <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, psoriasiform <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">exacerbation of psoriasis</span>; <span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span>: Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and generalized and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">localized rash</span>; <span class="Italics">Respiratory</span>: <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> (predominantly in patients with pre-existing bronchospastic disease), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>; <span class="Italics">Endocrine</span>: Masked symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> patients <span class="Italics">[see Warnings and Precautions (<a href="#s15">5.7</a>)]</span>; <span class="Italics">Special Senses</span>: <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="437860" conceptname="Choroidal detachment">choroidal detachment</span> following filtration surgery, <span class="product-label-link" type="condition" conceptid="4105178" conceptname="Cystoid macular edema">cystoid macular edema</span>, decreased corneal sensitivity, pseudopemphigoid, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, refractive changes, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>; <span class="Italics">Urogenital</span>: Decreased libido, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, Peyronie's disease, <span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">retroperitoneal fibrosis</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-6.2.1"></a><p></p>
<p class="First">The following reactions have been identified during post-marketing use of brimonidine tartrate ophthalmic solutions, timolol ophthalmic solutions, or both in combination, in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to brimonidine tartrate ophthalmic solutions, timolol ophthalmic solutions, or a combination of these factors, include: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, eyelid <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> extending to the cheek or forehead, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">keratoconjunctivitis sicca</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (including <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, eyelid <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and vasodilation), and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. In infants, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> have been reported <span class="Italics">[see Contraindications (<a href="#e7">4.3</a>) and Use in Specific Populations (<a href="#s40">8.4</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Bold">Oral Timolol/Oral Beta-blockers</span></p>
<p>The following additional adverse reactions have been reported in clinical experience with ORAL timolol maleate or other ORAL beta-blocking agents and may be considered potential effects of ophthalmic timolol maleate: <span class="Italics">Allergic</span>: Erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> combined with aching and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> with <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>; <span class="Italics">Body as a whole</span>: Decreased exercise tolerance, extremity <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>; <span class="Italics">Cardiovascular</span>: <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">Vasodilatation</span>, worsening of <span class="product-label-link" type="condition" conceptid="4109870" conceptname="Arterial insufficiency">arterial insufficiency</span>; <span class="Italics">Digestive</span>: <span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">Gastrointestinal pain</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>, mesenteric <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>;  <span class="Italics">Hematologic</span>: <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, nonthrombocytopenic <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>; <span class="Italics">Endocrine</span>: <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>; <span class="Italics">Skin</span>: Increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>; <span class="Italics">Musculoskeletal</span>: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>;  <span class="Italics">Nervous System/Psychiatric</span>: An acute reversible syndrome characterized by <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> for time and place, decreased performance on neuropsychometrics, diminished concentration, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, local <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, reversible mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> progressing to <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonia</span>, slightly clouded sensorium, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>; <span class="Italics">Respiratory</span>: <span class="product-label-link" type="condition" conceptid="4279071" conceptname="Obstruction of bronchus">Bronchial obstruction</span>, <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">rales</span>; <span class="Italics">Urogenital</span>: Urination difficulties.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s27"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Antihypertensives/Cardiac Glycosides
</h2>
<p class="First">Because <span class="Bold">COMBIGAN<span class="Sup">®</span></span> may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with <span class="Bold">COMBIGAN<span class="Sup">®</span></span> is advised.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Beta-adrenergic Blocking Agents
</h2>
<p class="First">Patients who are receiving a beta-adrenergic blocking agent orally and <span class="Bold">COMBIGAN<span class="Sup">®</span></span> should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.  The concomitant use of two topical beta-adrenergic blocking agents is not recommended.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Calcium Antagonists
</h2>
<p class="First">Caution should be used in the co-administration of beta-adrenergic blocking agents, such as <span class="Bold">COMBIGAN<span class="Sup">®</span></span>, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, <span class="product-label-link" type="condition" conceptid="439846" conceptname="Left heart failure">left ventricular failure</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In patients with impaired cardiac function, co-administration should be avoided.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Catecholamine-depleting Drugs
</h2>
<p class="First">Close observation of the patient is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, which may result in <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-7.5"></a><p></p>
<h2>7.5 CNS Depressants
</h2>
<p class="First">Although specific drug interaction studies have not been conducted with <span class="Bold">COMBIGAN<span class="Sup">®</span></span>, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Digitalis and Calcium Antagonists
</h2>
<p class="First">The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-7.7"></a><p></p>
<h2>7.7 CYP2D6 Inhibitors
</h2>
<p class="First">Potentiated systemic beta-blockade (e.g., decreased heart rate, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Tricyclic Antidepressants
</h2>
<p class="First">Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with <span class="Bold">COMBIGAN<span class="Sup">®</span></span> in humans can lead to resulting interference with the IOP-lowering effect. Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-7.9"></a><p></p>
<h2>7.9 Monoamine Oxidase Inhibitors
</h2>
<p class="First">Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side effect such as <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Caution, however, is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s37"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s38"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<p class="First">Pregnancy Category C: <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies have been performed in animals.
</p>
<p>Brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits. The highest doses of brimonidine tartrate in rats (2.5 mg/kg/day) and rabbits (5 mg/kg/day) achieved AUC exposure values 580 and 37-fold higher, respectively, than similar values estimated in humans treated with <span class="Bold">COMBIGAN<span class="Sup">®</span></span>, 1 drop in both eyes twice daily.
</p>
<p><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day [4,200 times the maximum recommended human ocular dose of 0.012 mg/kg/day on a mg/kg basis (MRHOD)] demonstrated no evidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. Doses of 1,000 mg/kg/day (83,000 times the MRHOD) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses 8,300 times the MRHOD without apparent maternotoxicity.
</p>
<p>There are no adequate and well-controlled studies in pregnant women; however, in animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent. Because animal reproduction studies are not always predictive of human response, <span class="Bold">COMBIGAN<span class="Sup">®</span></span> should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s39"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">Timolol has been detected in human milk following oral and ophthalmic drug administration. It is not known whether brimonidine tartrate is excreted in human milk, although in animal studies, brimonidine tartrate has been shown to be excreted in breast milk. Because of the potential for serious adverse reactions from <span class="Bold">COMBIGAN<span class="Sup">®</span></span> in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s40"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First"><span class="Bold">COMBIGAN<span class="Sup">®</span></span> is contraindicated in children under the age of 2 years <span class="Italics">[see Contraindications (<a href="#e7">4.3</a>)]</span>. During post-marketing surveillance, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> have been reported in infants receiving brimonidine. The safety and effectiveness of brimonidine tartrate and timolol maleate have not been studied in children below the age of 2 years.
</p>
<p>The safety and effectiveness of <span class="Bold">COMBIGAN<span class="Sup">®</span></span> have been established in the age groups 2 – 16 years of age. Use of <span class="Bold">COMBIGAN<span class="Sup">®</span></span> in these age groups is supported by evidence from adequate and well-controlled studies of <span class="Bold">COMBIGAN<span class="Sup">®</span></span> in adults with additional data from a study of the concomitant use of brimonidine tartrate ophthalmic solution 0.2% and timolol maleate ophthalmic solution in pediatric <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> patients (ages 2 to 7 years).  In this study, brimonidine tartrate ophthalmic solution 0.2% was dosed three times a day as adjunctive therapy to beta-blockers. The most commonly observed adverse reactions were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (50%-83% in patients 2 to 6 years) and decreased alertness. In pediatric patients 7 years of age or older (&gt;20 kg), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> appears to occur less frequently (25%). Approximately 16% of patients on brimonidine tartrate ophthalmic solution discontinued from the study due to <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s41"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and other adult patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s42"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE
</h1>
<p class="First">There have been reports of inadvertent overdosage with timolol ophthalmic solution resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. Very limited information exists on accidental ingestion of brimonidine in adults alone or in combination. Symptoms of brimonidine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> have been reported in neonates, infants, and children receiving brimonidine ophthalmic solutions as part of medical treatment of <span class="product-label-link" type="condition" conceptid="374139" conceptname="Buphthalmos">congenital glaucoma</span> or by accidental oral ingestion <span class="Italics">[see Use in Specific Populations (<a href="#s40">8.4</a>)]</span>. Treatment of an oral <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> includes supportive and symptomatic therapy; a patent airway should be maintained.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s43"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First"><span class="Bold">COMBIGAN<span class="Sup">®</span></span> (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, sterile, is a relatively selective alpha-2 adrenergic receptor agonist with a non-selective beta-adrenergic receptor inhibitor (topical intraocular pressure lowering agent).
</p>
<p>The structural formulae are:
</p>
<p>Brimonidine tartrate:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=feaf1480-a4b8-4486-992a-96be3a596243&amp;name=structuralformula1.jpg">
</div>
<p>5-bromo-6-(2-imidazolidinylideneamino) quinoxaline L-tartrate; MW= 442.24
</p>
<p>Timolol maleate:
</p>
<div class="Figure">
<a name="f02"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=feaf1480-a4b8-4486-992a-96be3a596243&amp;name=structuralformula2.jpg">
</div>
<p>(-)-1-(<span class="Italics">tert</span>-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)-oxy]-2-propanol maleate (1:1) (salt); MW= 432.50 as the maleate salt
</p>
<p>In solution, <span class="Bold">COMBIGAN<span class="Sup">®</span></span> (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% has a clear, greenish-yellow color. It has an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of 260-330 mOsmol/kg and a pH during its shelf life of 6.5-7.3.
</p>
<p>Brimonidine tartrate appears as an off-white, or white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>-yellow powder and is soluble in both water (1.5 mg/mL) and in the product vehicle (3 mg/mL) at pH 7.2. Timolol maleate appears as a white, odorless, crystalline powder and is soluble in water, methanol, and alcohol.
</p>
<p>Each mL of <span class="Bold">COMBIGAN<span class="Sup">®</span></span> contains the active ingredients brimonidine tartrate 0.2% and timolol 0.5% with the inactive ingredients benzalkonium chloride 0.005%; sodium phosphate, monobasic; sodium phosphate, dibasic; purified water; and hydrochloric acid and/or sodium hydroxide to adjust pH.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s44"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s45"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First"><span class="Bold">COMBIGAN<span class="Sup">®</span></span> is comprised of two components: brimonidine tartrate and timolol. Each of these two components decreases elevated intraocular pressure, whether or not associated with <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span> and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>.
</p>
<p><span class="Bold">COMBIGAN<span class="Sup">®</span></span> is a relatively selective alpha-2 adrenergic receptor agonist with a non-selective beta-adrenergic receptor inhibitor. Both brimonidine and timolol have a rapid onset of action, with peak ocular hypotensive effect seen at two hours post-dosing for brimonidine and one to two hours for timolol.
</p>
<p>Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.
</p>
<p>Timolol maleate is a beta<span class="Sub">1</span> and beta<span class="Sub">2</span> adrenergic receptor inhibitor that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s46"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Bold">Absorption</span></p>
<p>Systemic absorption of brimonidine and timolol was assessed in healthy volunteers and patients following topical dosing with <span class="Bold">COMBIGAN<span class="Sup">®</span></span>. Normal volunteers dosed with one drop of <span class="Bold">COMBIGAN<span class="Sup">®</span></span> twice daily in both eyes for seven days showed peak plasma brimonidine and timolol concentrations of 30 pg/mL and 400 pg/mL, respectively. Plasma concentrations of brimonidine peaked at 1 to 4 hours after ocular dosing. Peak plasma concentrations of timolol occurred approximately 1 to 3 hours post-dose.
</p>
<p>In a crossover study of <span class="Bold">COMBIGAN<span class="Sup">®</span></span>, brimonidine tartrate 0.2%, and timolol 0.5% administered twice daily for 7 days in healthy volunteers, the mean brimonidine area-under-the-plasma-concentration-time curve (AUC) for <span class="Bold">COMBIGAN<span class="Sup">®</span></span> was 128 ± 61 pg•hr/mL versus 141 ± 106 pg•hr/mL for the respective monotherapy treatments; mean C<span class="Sub">max</span> values of brimonidine were comparable following <span class="Bold">COMBIGAN<span class="Sup">®</span></span> treatment versus monotherapy (32.7 ± 15 pg/mL versus 34.7 ± 22.6 pg/mL, respectively).  Mean timolol AUC for <span class="Bold">COMBIGAN<span class="Sup">®</span></span> was similar to that of the respective monotherapy treatment (2919 ± 1679 pg•hr/mL versus 2909 ± 1231 pg•hr/mL, respectively); mean C<span class="Sub">max</span> of timolol was approximately 20% lower following <span class="Bold">COMBIGAN<span class="Sup">®</span></span> treatment versus monotherapy.
</p>
<p>In a parallel study  in patients dosed twice daily with <span class="Bold">COMBIGAN<span class="Sup">®</span></span>, twice daily with timolol 0.5%, or three times daily with brimonidine tartrate 0.2%, one-hour post dose plasma concentrations of timolol and brimonidine  were approximately 30-40% lower with <span class="Bold">COMBIGAN<span class="Sup">®</span></span> than their respective monotherapy values. The lower plasma brimonidine concentrations with <span class="Bold">COMBIGAN<span class="Sup">®</span></span> appears to be due to twice-daily dosing for <span class="Bold">COMBIGAN<span class="Sup">®</span></span> versus three-times dosing with brimonidine tartrate 0.2%.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Bold">Distribution</span></p>
<p>The protein binding of timolol is approximately 60%. The protein binding of brimonidine has not been studied.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-11.2.3"></a><p></p>
<p class="First"><span class="Bold">Metabolism</span></p>
<p>In humans, brimonidine is extensively metabolized by the liver. Timolol is partially metabolized by the liver.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-11.2.4"></a><p></p>
<p class="First"><span class="Bold">Excretion</span></p>
<p>In the crossover study in healthy volunteers, the plasma concentration of brimonidine declined with a systemic half-life of approximately 3 hours. The apparent systemic half-life of timolol was about 7 hours after ocular administration.
</p>
<p>Urinary excretion is the major route of elimination of brimonidine and its metabolites.  Approximately 87% of an orally-administered radioactive dose of brimonidine was eliminated within 120 hours, with 74% found in the urine.  Unchanged timolol and its metabolites are excreted by the kidney.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-11.2.5"></a><p></p>
<p class="First"><span class="Bold">Special Populations</span></p>
<p><span class="Bold">COMBIGAN<span class="Sup">®</span></span> has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.
</p>
<p><span class="Bold">COMBIGAN<span class="Sup">®</span></span> has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.
</p>
<p>A study of patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> showed that timolol was not readily removed by dialysis.  The effect of dialysis on brimonidine pharmacokinetics in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> is not known.
</p>
<p>Following oral administration of timolol maleate, the plasma half-life of timolol is essentially unchanged in patients with moderate <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s52"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s53"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">With brimonidine tartrate, no compound-related carcinogenic effects were observed in either mice or rats following a 21-month and 24-month study, respectively. In these studies, dietary administration of brimonidine tartrate at doses up to 2.5 mg/kg/day in mice and 1 mg/kg/day in rats achieved 150 and 210 times, respectively, the plasma C<span class="Sub">max</span> drug concentration in humans treated with one drop of <span class="Bold">COMBIGAN<span class="Sup">®</span></span> into both eyes twice daily, the recommended daily human dose.
</p>
<p>In a two-year study of timolol maleate administered orally to rats, there was a statistically significant increase in the incidence of adrenal <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytomas</span> in male rats administered 300 mg/kg/day [approximately 25,000 times the maximum recommended human ocular dose of 0.012 mg/kg/day on a mg/kg basis (MRHOD)].  Similar differences were not observed in rats administered oral doses equivalent to approximately 8,300 times the daily dose of <span class="Bold">COMBIGAN<span class="Sup">®</span></span> in humans.
</p>
<p>In a lifetime oral study of timolol maleate in mice, there were statistically significant increases in the incidence of benign and malignant pulmonary tumors, benign uterine <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> and mammary adenocarcinomas in female mice at 500 mg/kg/day, (approximately 42,000 times the MRHOD), but not at 5 or 50 mg/kg/day (approximately 420 to 4,200 times higher, respectively, than the MRHOD). In a subsequent study in female mice, in which post-mortem examinations were limited to the uterus and the lungs, a statistically significant increase in the incidence of pulmonary tumors was again observed at 500 mg/kg/day.
</p>
<p>The increased occurrence of mammary adenocarcinomas was associated with elevations in serum prolactin which occurred in female mice administered oral timolol at 500 mg/kg/day, but not at doses of 5 or 50 mg/kg/day. An increased incidence of mammary adenocarcinomas in rodents has been associated with administration of several other therapeutic agents that elevate serum prolactin, but no correlation between serum prolactin levels and mammary tumors has been established in humans. Furthermore, in adult human female subjects who received oral dosages of up to 60 mg of timolol maleate (the maximum recommended human oral dosage), there were no clinically meaningful changes in serum prolactin.
</p>
<p>Brimonidine tartrate was not mutagenic or clastogenic in a series of <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> studies including the Ames bacterial reversion test, chromosomal aberration assay in Chinese Hamster Ovary (CHO) cells, and three <span class="Italics">in vivo</span> studies in CD-1 mice: a host-mediated assay, cytogenetic study, and dominant lethal assay.
</p>
<p>Timolol maleate was devoid of mutagenic potential when tested <span class="Italics">in vivo</span> (mouse) in the micronucleus test and cytogenetic assay (doses up to 800 mg/kg) and <span class="Italics">in vitro</span> in a neoplastic cell transformation assay (up to 100 mcg/mL). In Ames tests the highest concentrations of timolol employed, 5,000 or 10,000 mcg/plate, were associated with statistically significant elevations of revertants observed with tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA100 (in seven replicate assays), but not in the remaining three <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>. In the assays with tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA100, no consistent dose response relationship was observed, and the ratio of test to control revertants did not reach 2. A ratio of 2 is usually considered the criterion for a positive Ames test.
</p>
<p>Reproduction and fertility studies in rats with timolol maleate and in rats with brimonidine tartrate demonstrated no adverse effect on male or female fertility at doses up to approximately 100 times the systemic exposure following the maximum recommended human ophthalmic dose of <span class="Bold">COMBIGAN<span class="Sup">®</span></span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s54"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<p class="First">Clinical studies were conducted to compare the IOP-lowering effect over the course of the day of <span class="Bold">COMBIGAN<span class="Sup">®</span></span> administered twice a day (BID) to individually-administered brimonidine tartrate ophthalmic solution, 0.2% administered three times per day (TID) and timolol maleate ophthalmic solution, 0.5% BID in patients with <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span>. <span class="Bold">COMBIGAN<span class="Sup">®</span></span> BID provided an additional 1 to 3 mm Hg decrease in IOP over brimonidine treatment TID and an additional 1 to 2 mm Hg decrease over timolol treatment BID during the first 7 hours post dosing.  However, the IOP-lowering of <span class="Bold">COMBIGAN<span class="Sup">®</span></span> BID was less (approximately 1-2 mm Hg) than that seen with the concomitant administration of 0.5% timolol BID and 0.2% brimonidine tartrate TID. <span class="Bold">COMBIGAN<span class="Sup">®</span></span> administered BID had a favorable safety profile versus concurrently administered brimonidine TID and timolol BID in the self-reported level of severity of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> for patients over age 40.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s55"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First"><span class="Bold">COMBIGAN<span class="Sup">®</span></span> is supplied sterile, in white opaque plastic LDPE bottles and tips, with blue high impact polystyrene (HIPS) caps as follows:
</p>
<p>5 mL in 10 mL bottle           NDC 0023-9211-05<br>10 mL in 10 mL bottle         NDC 0023-9211-10
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Storage:</span> Store at 15°-25°C (59°-77°F). Protect from light.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s57"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">Patients with bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>, <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, second or third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> should be advised not to take this product <span class="Italics">[see Contraindications (<a href="#s5">4.1</a>, <a href="#s6">4.2</a>)]</span>.
</p>
<p>Patients should be instructed that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Serious damage to the eye and subsequent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> may result from using contaminated solutions <span class="Italics">[see Warnings and Precautions (<a href="#s18">5.10</a>)]</span>. Always replace the cap after using. If solution changes color or becomes cloudy, do not use. Do not use the product after the expiration date marked on the bottle.
</p>
<p>Patients also should be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g., <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>), they should immediately seek their physician's advice concerning the continued use of the present multidose container.
</p>
<p>If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.
</p>
<p>Patients should be advised that <span class="Bold">COMBIGAN<span class="Sup">®</span></span> contains benzalkonium chloride which may be absorbed by soft contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of <span class="Bold">COMBIGAN<span class="Sup">®</span></span>.
</p>
<p>As with other similar medications, <span class="Bold">COMBIGAN<span class="Sup">®</span></span> may cause <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and/or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> in some patients. Patients who engage in hazardous activities should be cautioned of the potential for a decrease in mental alertness.
</p>
<p>© 2013 Allergan, Inc., Irvine, CA  92612, U.S.A.<br>® marks owned by Allergan, Inc.<br>Patented. See: www.allergan.com/products/patent_notices<br>Made in the U.S.A.
</p>
<p><a name="f03"></a><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=feaf1480-a4b8-4486-992a-96be3a596243&amp;name=allerganlogo.jpg"></p>
<p>72060US14
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s58"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">
ALLERGAN
</span></p>
<p>
NDC 0023-9211-05
</p>
<p><span class="Bold Italics">Combigan</span><span class="Sup">®</span></p>
<p><span class="Bold">
(brimonidine tartrate/<br>timolol maleate<br>ophthalmic solution)<br>0.2%/0.5%
</span></p>
<p><span class="Bold">
Rx only
</span></p>
<p><span class="Bold">
5 mL         sterile
</span></p>
<div class="Figure">
<a name="f05"></a><img alt="5 mL Bottle Dropper Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=feaf1480-a4b8-4486-992a-96be3a596243&amp;name=carton.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>COMBIGAN 		
					</strong><br><span class="contentTableReg">brimonidine tartrate, timolol maleate solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0023-9211</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>brimonidine tartrate</strong> (brimonidine) </td>
<td class="formItem">brimonidine tartrate</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>timolol maleate</strong> (timolol anhydrous) </td>
<td class="formItem">timolol anhydrous</td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzalkonium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium phosphate, monobasic</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, dibasic</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0023-9211-03</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2.5 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0023-9211-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0023-9211-10</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021398</td>
<td class="formItem">11/14/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Allergan, Inc.
							(144796497)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Allergan, Inc.</td>
<td class="formItem"></td>
<td class="formItem">362898611</td>
<td class="formItem">MANUFACTURE(0023-9211)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f39d9b4d-1cc3-4198-82bf-4bd976bdd360</div>
<div>Set id: feaf1480-a4b8-4486-992a-96be3a596243</div>
<div>Version: 8</div>
<div>Effective Time: 20131120</div>
</div>
</div> <div class="DistributorName">Allergan, Inc.</div></p>
</body></html>
